FDA has issued a draft guidance to help sponsors avoid reaching false conclusions about a drug’s effects in clinical trials with multiple endpoints.
The draft guidance, Multiple Endpoints in Clinical Trials, describes strategies for grouping and ordering endpoints for analysis and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?